Receptor-driven identification of novel human A3 adenosine receptor antagonists as potential therapeutic agents

Methods in Enzymology

Volumn 485, Issue C, 2010, Pages 225-244

  Paoletta, Silvia ^a   Federico, Stephanie ^b   Spalluto, Giampiero ^b   Moro, Stefano ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A3 RECEPTOR ANTAGONIST;

BOOK; CRYSTAL STRUCTURE; DRUG IDENTIFICATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; MOLECULAR DOCKING; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 78049489779     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381296-4.00013-0     Document Type: Chapter

References (24)

1. Borea P.A., Gessi S., Bar-Yehuda S., Fishman P. A3 adenosine receptor: pharmacology and role in disease. Handb. Exp. Pharmacol. 2009, 193:297-327.
2. Cheong S.L., Dolzhenko A., Kachler S., Paoletta S., Federico S., Cacciari B., Dolzhenko A., Klotz K.N., Moro S., Spalluto G., Pastorin G. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition. J. Med. Chem. 2010, 53:3361-3375.
3. Cherezov V., Rosenbaum D.M., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., Choi H.J., Kuhn P., Weis W.I., Kobilka B.K., Stevens R.C. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318:1258-1265.
4. Gao Z.G., Kim S.K., Biadatti T., Chen W., Lee K., Barak D., Kim S.G., Johnson C.R., Jacobson K.A. Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary. J. Med. Chem. 2002, 45:4471-4484.
5. Gao Z.G., Chen A., Barak D., Kim S.K., Muller C.E., Jacobson K.A. Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary. J. Biol. Chem. 2002, 277:19056-19063.
6. Gao Z.G., Kim S.K., Gross A.S., Chen A., Blaustein J.B., Jacobson K.A. Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary. Mol. Pharmacol. 2003, 63:1021-1031.
7. Jaakola V.P., Griffith M.T., Hanson M.A., Cherezov V., Chien E.Y., Lane J.R., Ijzerman A.P., Stevens R.C. Science 2008, 322:1211-1217.
8. Jaakola V.P., Lane J.R., Lin J.Y., Katritch V., Ijzerman A.P., Stevens R.C. J. Biol. Chem. 2010, 285:13032-13044.
9. Jacobson K.A., Gao Z.G. Adenosine receptors as therapeutic targets. Nat. Rev. Drug Discov. 2006, 5:247-264.
10. Jacobson K.A., Klutz A.M., Tosh D.K., Ivanov A.A., Preti D., Baraldi P.G. Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering. Handb. Exp. Pharmacol. 2009, 193:123-159.
11. Jiang Q., Van Rhee A.M., Kim J., Yehle S., Wess J., Jacobson K.A. Mol. Pharmacol. 1996, 50:512-521.
12. Kim J., Wess J., van Rhee A.M., Schoneberg T., Jacobson K.A. J. Biol. Chem. 1995, 270:13987-13997.
13. Kim J., Jiang Q., Glashofer M., Yehle S., Wess J., Jacobson K.A. Mol. Pharmacol. 1996, 49:683-691.
14. Lenzi O., Colotta V., Catarzi D., Varano F., Poli D., Filacchioni G., Varani K., Vincenzi F., Borea P.A., Paoletta S., Morizzo E., Moro S. 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition. J. Med. Chem. 2009, 52:7640-7652.
15. Martinelli A., Tuccinardi T. Molecular modeling of adenosine receptors: new results and trends. Med. Res. Rev. 2008, 28:247-277.
16. Morizzo E., Federico S., Spalluto G., Moro S. Human A3 adenosine receptor as versatile G protein-coupled receptor example to validate the receptor homology modeling technology. Curr. Pharm. Des. 2009, 15:4069-4084.
17. Moro S., Spalluto G., Jacobson K.A. Techniques: Recent developments in computer-aided engineering of GPCR ligands using the human adenosine A3 receptor as an example. Trends Pharmacol. Sci. 2005, 26:44-51.
18. Moro S., Gao Z.G., Jacobson K.A., Spalluto G. Progress in the pursuit of therapeutic adenosine receptor antagonists. Med. Res. Rev. 2006, 26:131-159.
19. Moro S., Deflorian F., Bacilieri M., Spalluto G. Novel strategies for the design of new potent and selective human A3 receptor antagonists: an update. Curr. Med. Chem. 2006, 13:639-645.
20. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., Le Trong I., Teller D.C., Okada T., Stenkamp R.E., Yamamoto M., Miyano M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000, 289:739-745.
21. Pastorin G., Federico S., Paoletta S., Corradino M., Cateni F., Cacciari B., Klotz K.N., Gao Z.G., Jacobson K.A., Spalluto G., Moro S. Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition process. Bioorg. Med. Chem. 2010, 18:2524-2536.
22. Rosenbaum D.M., Cherezov V., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., Choi H.J., Yao X.J., Weis W.I., Stevens R.C., Kobilka B.K. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 2007, 318:1266-1273.
23. Taliani S., La Motta C., Mugnaini L., Simorini F., Salerno S., Marini A.M., Da Settimo F., Cosconati S., Cosimelli B., Greco G., Limongelli V., Marinelli L., et al. Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation. J. Med. Chem. 2010, 53:3954-3963.
24. Warne T., Serrano-Vega M.J., Baker J.G., Moukhametzianov R., Edwards P.C., Henderson R., Leslie A.G., Tate C.G., Schertler G.F. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 2008, 454:486-491.